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Summary
Invasive	fungal	infections	(IFI)	of	the	Central	Nervous	System	(IFI-	CNS)	and	Paranasal	
Sinuses	 (IFI-	PS)	 are	 rare,	 life-	threatening	 infections	 in	 haematologic	 patients,	 and	
their	management	remains	a	challenge	despite	the	availability	of	new	diagnostic	tech-
niques	and	novel	antifungal	agents.	In	addition,	analyses	of	large	cohorts	of	patients	
focusing	 on	 these	 rare	 IFI	 are	 still	 lacking.	 Between	 January	 2010	 and	December	
2016,	89	consecutive	cases	of	Proven	(53)	or	Probable	(36)	IFI-	CNS	(71/89)	and	IFI-	PS	
(18/89)	were	collected	in	34	haematological	centres.	The	median	age	was	40	years	
(range	5-	79);	acute	 leukaemia	was	the	most	common	underlying	disease	 (69%)	and	
29%	of	cases	received	a	previous	allogeneic	stem	cell	transplant.	Aspergillus spp. were 
the	most	common	pathogens	(69%),	followed	by	mucormycetes	(22%),	Cryptococcus 
spp.	(4%)	and	Fusarium spp.	(2%).	The	lung	was	the	primary	focus	of	fungal	infection	
(48%	of	cases).	The	nervous	system	biopsy	was	performed	in	10%	of	IFI-	CNS,	and	a	
sinus	biopsy	was	performed	in	56%	of	IFI-	PS	(P	=	0.03).	The	Galactomannan	test	on	
cerebrospinal	fluid	has	been	performed	in	42%	of	IFI-	CNS	(30/71),	and	it	was	positive	
in	67%.	Eighty-	four	pts	received	a	first-	line	antifungal	therapy	with	Amphotericine	B	
in	58%	of	cases,	Voriconazole	 in	31%	and	both	 in	11%.	Moreover,	58%	of	patients	
received	2	or	more	lines	of	therapy	and	38%	were	treated	with	a	combination	of	2	or	
more	antifungal	drugs.	The	median	duration	of	antifungal	therapy	was	60	days	(range	
5-	835).	A	surgical	intervention	was	performed	in	26%	of	cases	but	only	10%	of	IFI-	
CNS	underwent	neurosurgical	 intervention.	The	overall	response	rate	to	antifungal	
therapy	(complete	or	partial	response)	was	57%,	and	1-	year	overall	survival	was	32%	
without	 significant	 differences	 between	 IFI-	CNS	 and	 IFI-	PS.	 The	 overall	mortality	
was	69%	but	the	IFI	attributable	mortality	was	33%.	Mortality	of	IFI-	CNS/PS	remains	
high	but,	compared	to	previous	historical	data,	it	seems	to	be	reduced	probably	due	
to	the	availability	of	newer	antifungal	drugs.	The	results	arising	from	this	large	con-
temporary	 cohort	of	 cases	may	allow	a	more	effective	diagnostic	 and	 therapeutic	
management	of	these	very	rare	IFI	complications	in	haematologic	patients.
K E Y W O R D S
Aspergillosis,	fungal	CNS	infectious,	haematological	diseases,	leukaemia,	neurologic	
complications,	Zygomicosis
1  | INTRODUC TION
Invasive	 fungal	 infections	 (IFI)	 of	 the	 Central	 Nervous	 System	
(IFI-	CNS)	and	those	of	the	Paranasal	Sinuses	 (IFI-	PS)	are	rare,	 life-	
threatening	infections	in	haematologic	patients,	and	their	manage-
ment	remains	a	challenge	despite	the	availability	of	new	diagnostic	
techniques	and	novel	antifungal	agents.1-8	There	is	a	lack	of	recent	
epidemiologic	studies	with	a	proper	number	of	cases	reporting	the	
outcome	of	 haematologic	 patients	with	 IFI	 involving	CNS	 and	PS,	
and	 therefore,	 the	 most	 appropriate	 diagnostic	 and	 therapeutic	
approach	remain	to	be	clearly	defined.	In	fact,	in	the	literature,	we	
found	only	case	reports	or	small	retrospective	studies,	more	often	
not recent.1,9-13	 The	 most	 frequently	 reported	 pathogens	 were	
moulds	 and	 especially	Aspergillus	 and	Mucormycetes.1,2,6,14,15	 The	
therapeutic	 management	 of	 these	 infectious	 complications	 is	 still	
very	complex	and	heterogeneous,	and	recent	studies	on	the	efficacy	
of	new	antimycotic	drugs	are	limited	so	that	there	is	no	clear	stan-
dard	of	 care	currently	available.	For	 these	 reasons,	we	decided	 to	
carry	out	a	study	providing	an	update	on	current	epidemiology	and	
outcome	of	IFI-	CNS	and	IFI-	PS	occurring	in	haematological	patients	
in	recent	years	aiming	to	improve	the	knowledge	and	management	
of	these	serious	and	rare	infectious	complications.
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2  | PATIENTS AND METHODS
Between	January	2010	and	December	2016,	we	collected	all	cases	of	
IFI-	CNS	and	IFI-	PS	consecutively	observed	in	26	Italian	haematology	
centres	belonging	to	the	SEIFEM	group	and	in	8	Haematology	centres	
of	the	St.	Petersburg,	Russia.	The	study	was	carried	out	after	approval	
by	the	local	ethics	committees	and	the	local	health	authorities.
The	 patients’	 privacy	 was	 preserved	 and	 each	 haematological	
centre	 reported	 an	 identifying	 code	 for	 each	 case.	All	 the	 centres	
involved	performed	 the	similar	diagnostic	workup	 including	micro-
biological	 [i.e,	 research	 of	 indirect	 biomarkers:	 serum	 β-	D-	Glucan,	
Galactomannan	(GM)	on	blood,	cerebrospinal	fluid	or	other	sites]	and	
radiological	investigations	(i.e,	computerised	tomography	[CT]	and/
or	magnetic	 resonance	 imaging	 [MRI]).	 For	 each	 case	 observed,	 a	
standardised	Case	Report	Form	(CRF)	was	filled	out	containing	infor-
mation	regarding	the	haematological	disease	and	its	phase	and	status	
(induction,	consolidation	or	salvage	phase,	remission,	relapse	or	resis-
tant	disease	status);	risk	factors	for	IFI	(neutropenia	and	its	severity,	
previous	stem	cell	 transplantation,	Graft	Vs	Host	Disease	 [GVHD],	
steroid	 therapy,	 diabetes,	 previous	history	of	 IFI,	 chemotherapy	 in	
the	previous	30	days,	type	and	length	of	antifungal	prophylaxis);	the	
characteristics	of	 IFI	 (clinical	symptoms,	site	of	 infection,	positivity	
of	direct	and	indirect	tests,	histological	and	cultural	data,	autopsy	re-
port);	the	therapy	performed	(including	pharmacological	and	surgical	
treatment),	the	outcome	of	the	infection	and	cause	of	death.
2.1 | Definitions
Severe	 neutropenia	 was	 defined	 as	 a	 number	 of	 granulocytes	
(PMN)	 ≤500/mmc.	 Mild/moderate	 neutropenia	 was	 defined	 as	
PMN	 counts	 between	 500	 and	 1500/mmc.	 Steroid	 therapy	 has	
been	defined	as	the	use	of	prednisone	or	prednisolone	for	at	least	
7	days	at	a	dose	of	25	mg/day	or	1	mg/kg/day,	respectively.	Fever	
has	been	defined	according	to	the	IDSA	guidelines	as	an	increase	
in	body	temperature	≥38.3°C	once	or	≥38°C	for	more	than	1	hour.
Only	the	forms	of	Proven	and	Probable	IFI	were	considered	for	
this	study.	Each	IFI	case	was	defined	as	proven	or	probable	according	
to	 the	2008	criteria	established	by	 the	European	Organization	 for	
Research	and	Treatment	of	Cancer/Mycoses	Study	Group	(EORTC/
MSG).	The	IFI	was	declared	disseminated	when	it	involved	2	or	more	
non-	contiguous	sites.16
Complete	 or	 partial	 response	 (CR,	 PR)	 to	 therapy	was	 defined	
based	 on	 clinical,	 radiologic	 and/or	 mycological	 data	 as	 by	 the	
EORTC/MSG	 consensus	 group.	 Overall	 Response	 rate	 (ORR)	 was	
defined	as	CR+PR.16
In	 the	 case	of	 a	 patient’s	 death,	 the	 cause	of	 death	 had	 to	 be	
specified	as	one	of	 the	 following:	 (a)	mycosis	as	primary	cause,	 (b)	
haematological	 disease	 as	 primary	 cause	with	 concomitant	myco-
sis,	 (c)	haematological	disease	 in	 the	absence	of	mycosis,	 (d)	other	
causes.
We	considered	IFI	attributable	mortality	every	death	occurring	
without	evidence	of	active	haematological	disease	and	attributable	
only	to	infection	as	a	primary	cause	of	death.
2.2 | Statistical analysis
Descriptive	 statistics	 (including	 mean,	 standard	 deviation,	 me-
dian,	 range,	 frequency,	 percentages)	 were	 calculated	 to	 analyse	
and	compare	the	study	cohorts.	Overall	survival	 (OS)	 (defined	as	
the	interval	between	the	date	of	IFI	diagnosis	and	the	date	of	last	
follow-	up	or	 death)	was	 estimated	by	 the	Kaplan–Meier	 survival	
analysis.	OS	 curves	were	 compared	 using	 the	 log-	rank	 test.	 The	
independent	effect	of	demographic/clinical	predictors	on	OS	was	
assessed	by	multivariate	Cox	proportional	hazards	regression	anal-
ysis.	Adjusted	hazard	ratios	were	computed,	and	95%	confidence	
intervals	 (CI)	for	the	hazard	ratios	and	median	OS	time	estimates	
are	presented	 to	 assess	 the	precision	of	 the	 estimates	obtained.	
All	P-	values	are	 two-	sided,	with	statistical	 significance	evaluated	
at	 the	0.05	 alpha	 level.	 Fisher’s	 exact	 test	was	 used	 to	 compare	
group	 differences	 in	 categorical	 variables.	 Data	 were	 analysed	
with	MedCalc	software	(version	12.5.0.0;	MedCalc	Software	bvba,	
Ostend,	Belgium).
3  | RESULTS
3.1 | Characteristics of patients
During	 the	 study	period,	 89	 cases	 of	 Proven	 (53	 cases)	 or	 Probable	
(36	 cases)	 IFI	with	 localisation	 to	 the	CNS	and	PS	were	 recorded	 in	
34	Haematological	centres.	The	median	age	of	patients	was	40	years	
(range	 5-	79).	 The	 study	 population	 included	 23	 (26%)	 paediatric	 pa-
tients	(age	≤18	years).	The	demographic	characteristics	of	patients	and	
of	 the	underlying	haematological	 diseases	 at	 diagnosis	 are	 shown	 in	
Table	1.
The	majority	of	patients	had	an	acute	myeloid	(34%)	or	lymphoid	
(35%)	leukaemia.	Regarding	the	status	of	the	haematological	disease,	
most	of	 the	CNS/PS	 IFI	has	been	documented	 in	patients	with	an	
active	haematological	disease	(81%)	and	specifically	at	the	onset	of	
disease	(31/89,	35%)	or	during	its	relapse	(41/89,	46%).	Twenty-	nine	
per	 cent	of	patients	 (26/89)	had	previously	 received	an	allogeneic	
stem	cell	transplantation	(Allo-	SCT),	in	16/26	cases	from	unrelated	
donors,	in	5/26	from	an	HLA-	identical	family	donor	and	in	5/26	from	
a haploidentical donor.
Most	patients	had	neutropenia	at	the	onset	of	IFI	(74%,	66/89)	
of	 severe	 grade	 in	 49%	 of	 cases	 (44/89).	 Severe	 neutropenia	 has	
been	reported	more	frequently	in	patients	with	IFI-	PS	(P	=	0.0037).	
Patients	received	steroid	therapy	in	61/89	cases	(69%),	and	13	pa-
tients	(15%)	had	a	history	of	diabetes.
3.2 | Clinical manifestations and aetiology of IFI
The	most	common	presenting	symptoms	were	fever	in	65%	(58/89)	
of	cases	and	headache	in	26%	(23/89)	of	cases.	Regarding	neurologi-
cal	symptoms,	seizures	occurred	in	16	cases	(18%)	while	in	43	cases	
(48%)	 focal	 neurological	 symptoms	 (i.e,	 aphasia,	 dysarthria,	 diplo-
pia)	have	been	 reported,	with	or	without	a	concomitant	alteration	
of	 consciousness.	 Neurological	 disorders	 were	 significantly	 more	
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frequent	in	the	IFI-	CNS	(40/71	vs	3/18).	On	the	contrary,	rhinorrhea	
was	significantly	more	present	in	the	IFI-	PS	(5/18	vs	3/71)	(Table	1).
3.2.1 | Aetiological agents
Proven	infections	were	53/89	(60%),	48	caused	by	moulds	and	5	by	
yeasts.	Aspergillus spp.	has	been	documented	in	25	of	proven	cases,	
while the Mucorales	in	20	cases.	In	2	cases,	the	aetiologic	agent	was	
Fusarium spp.	 and	 in	 1	 case	 Scedosporium	 apiospermum	 (Table	1).	
Proven	 IFIs	 caused	 by	 yeasts	 were	 5:	 Cryptococcus spp.	 was	 iso-
lated	in	most	cases	(4/5)	while	in	one	case	the	aetiologic	agent	was	
Trichosporon	asahii.	The	probable	infections	were	36	(36/89,	40%),	
all with Aspergillus	aetiology.	Overall,	the	majority	of	IFI	were	caused	
by Aspergillus spp.	 (proven	+	probable	61/89,	70%).	The	specie	was	
available	in	19	cases:	A.	flavus	was	detected	in	10	cases	and	A.	fu-
migatus	in	9	cases.
TABLE  1 Patients	and	haematologic	disease	characteristics.	IFI	characteristics
All IFI- CNS IFI- PS P value
Patients	and	haematologic	disease
N°	of	cases 89 71 18
Age	mean	±	SD 39	±	22 37	±	22 46.6	±	19.4
median	(range) 40	(5-	79) 36	(5-	74) 47.5	(12-	79)
Haematologic	disease
AML 30	(34%) 22	(31%) 8	(44%) 0.4
ALL 31	(35%) 28	(39%) 3	(17%) 0.09
Chronic leukaemia 11	(12%) 9	(13%) 2	(11%) 0.9
MDS 4	(4%) 2	(3%) 2	(11%) 0.2
Aplasia 4	(4%) 5	(7%) 1	(6%) 0.9
NHL 6	(7%) 4/71	(6%) 2	(11%) 0.6
MM 1/71	(1%)
Disease	phase
Onset 31	(35%) 24	(33%) 7	(39%) 0.8
Relapse/refractory 41	(46%) 33	(46%) 8	(44%) 0.9
Consolidation 17	(19%) 14	(20%) 3	(17%) 0.9
PMN	<	500	at	onset	of	infection 44	(49%) 31/71	(44%) 13	(72%) 0.0037
Previous	Allo-	SCT 26/89	(29%) 24/71	(34%) 2/18	(11%) 0.08
IFI	characteristics
N°	of	cases 89 71 18
Proven 53	(60%) 38/71	(25%) 15/18	(83%) 0.03
Probable 36	(40%) 33/71	(46%) 3/18	(17%)
Presenting	symptoms
Headache 23	(26%) 20	(28%) 3	(17%)
Seizure 16	(18%) 16	(23%) 0
Fever 58	(65%) 46	(65%) 12	(67%)
Neurological	symptoms 43	(48%) 40	(56%) 3	(17%) 0.04
rhinorrhea 8	(9%) 3	(4%) 5	(28%)
Aetiology
Aspergillus spp. 61	(70%) 49	(69%) 12	(67%) 0.9
Mucorales 20	(22%) 15	(21%) 5	(28%) 0.5
Fusarium spp. 2	(2%) 1	(1%) 1	(6%)
Cryptococcus spp. 4	(4%) 4	(6%) 0
Trichosporum sp. 1	(1%) 1	(1%) 0
Scedosporium sp. 1	(1%) 1	(1%) 0
Isolate	IFI 27	(30%) 18	(25%) 9	(50%) 0.05
Disseminated	IFI 62	(70%) 53	(75%) 9	(50%) 0.05
AML,	acute	myeloid	leukaemia;	ALL,	acute	lymphoid	leukaemia;	MDS,	myelodysplastic	syndrome,	MM,	multiple	myeloma.
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3.2.2 | Localisation of IFI
There	were	71/89	cases	(80%)	of	CNS	involvement	(18/71-	25%	with	
isolated	localisation	in	the	CNS)	and	18/89	cases	(20%)	of	PS	involve-
ment	without	concomitant	CNS	involvement	(9/18	with	isolated	lo-
calisation	of	the	paranasal	sinuses).	The	PS	and	the	CNS	were	both	
involved	by	contiguity	in	15/89	cases	(17%).	The	IFI	was	disseminated	
(involvement	of	2	or	more	non-	contiguous	sites)	in	62/89	cases	(70%)	
with	 significant	prevalence	 in	 the	 cohort	of	 IFI-	CNS	 (53/71	cases-
	75%,	 vs	 9/18	 cases-	50%;	 P	=	0.05)	 (Table	1).	 The	 lungs	 have	 been	
identified	as	the	primary	focus	of	IFI	in	48%	of	cases.	Ten	of	20	(50%)	
cases	of	mucormycosis	had	only	CNS	and/or	PS	localisation.
3.3 | Diagnosis of IFI
The	diagnosis	was	made	by	biopsy	plus	a	histological	examination	in	
26/89	cases	(29%),	with	a	significant	higher	rate	of	PS	biopsies	com-
pared	to	CNS	biopsies	(18/26-	69%	vs	7/26-	26%;	P	=	0.005).	In	detail,	
in	the	IFI-	CNS	a	biopsy	of	brain	tissue	was	performed	only	in	10%	of	
cases	(7/71).	The	diagnosis	of	IFI	was	made	with	post-mortem	exami-
nation	in	6%	of	cases	(5/89).
Serum	 biomarkers	 coupled	 with	 radiological	 examinations	
(CT	±	MRI)	have	been	used	for	diagnosis	in	100%	of	cases.	Coltures	from	
infectious	sites,	blood	or	CSF,	were	performed	in	44/89	cases	(49%).
The	fungal	biomarkers	(GM,	(1-	3)-	β-	D-	Glucan,	cryptococcal	cap-
sular	antigen)	on	cerebrospinal	fluid	(CSF)	were	performed	in	34/71	
cases	of	 IFI-	CNS	(48%).	 In	all	4	cases	of	cerebral	cryptococcosis,	a	
TABLE  2 Diagnostic	procedures
Histopathological	examination 26/89	(29%)
PS	biopsy 18/26	(69%)
CNS	biopsy 7/26	(26%)
Other	site	biopsy 1/26	(5%)
Indirect	biomarkers
GM	test	(Blood	±	BAL) 89/89	(100%)
Indirect	biomarkers	on	CSF	(IFI-	CNS) 34/71	(48%)
GM test on CSF 30/71	(42%)
Positive	GM	test	on	CSF 20/30	(67%)
Cryptococcus Capsular Antigen Test on CSF 4/71	(6%)
Positive	capsular	antigen	test	on	CSF 4/4	(100%)
Fungal	coltures	(from	infectious	sites,	blood	or	
CSF)
44/89	(49%)
Radiological	examination	(CT±MRI) 88/89	(99%)
Post-	mortem	diagnosis 5/89	(6%)
CSF,	cerebrospinal	fluid;	BAL,	bronchoalveolar	lavage;	CT,	computerised	
tomography;	MRI,	magnetic	resonance	imaging.
ALL IFI- CNS IFI- PS P value
N°	of	cases 89 71 18
Drug	therapy 84	(94%) 66	(93%) 18	(100%) 0.57
Line	of	therapy
1td 35	(42%) 30	(45%) 5	(28%)
≥2	td 49	(58%) 36	(55%) 13	(72%) 0.28
Combination therapy 32	(38%) 21	(32%) 11	(61%) 0.03
Length	of	therapy
mean	±	SD 122	±	168 131,8	±	185 85,9	±	70
median	(range) 60(5-	835) 60(5-	835) 59(6-	220)
Surgical	resection 22/84	(26%) CNS	surgery:	7/66	
(10%)	
Other	sites	surgery:	
9/66	(14%)
PS	surgery	6/18	
(33%)
0.028
Response	to	treatment
ORR 48	(57%) 36	(54%) 12	(67%) 0.57
CR 29	(34%) 22	(33%) 7	(39%) 0.78
PR 19	(23%) 14	(21%) 5	(28%) 0.54
NR 36	(43%) 30	(46%) 6	(33%) 0.4
Outcome
Alive 28	(31%) 23	(32%) 5	(28%) 0.77
Deaths 61	(69%) 48	(68%) 13	(72%)
Attributable	mortality 20/61	(33%) 14/48	(29%) 6/13	(46%) 0.32
Mortality	for	HD	+	IFI 27/61	(44%) 25/48	(52%) 2/13	(15%) 0.026
HD,	haematologic	disease;	ORR,	overall	response	rate;	CR,	complete	response;	PR,	partial	response;	
NR,	not	response.
TABLE  3  IFI-	therapy,	response	and	
outcome
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CSF	 positivity	 of	 the	 cryptococcal	 capsular	 antigen	 was	 reported	
(4/4,	100%).	Galactomannan	(GM)	on	CSF	was	tested	in	30/71	(42%)	
of	IFI-	CNS,	and	it	was	positive	in	20/30	(67%)	(Table	2).
3.4 | Antifungal treatment
3.4.1 | Antifungal prophylaxis
Overall,	55	patients	(62%)	received	antifungal	prophylaxis	before	the	
onset	of	 IFI.	 In	detail,	28/55	received	Fluconazole	 (FLUCO),	14/55	
Posaconazole	 (POSA),	 5/55	 Itraconazole	 (ITRA),	 3/55	 liposomal	
Amphotericin	B	(AMB),	3/55	Voriconazole	(VORI),	1/55	Caspofungin	
(CASPO)	 and	 1/55	 Micafungin.	 The	 mean	 duration	 of	 antifungal	
prophylaxis	was	 18.5	days.	 None	 of	 the	 patients	with	 a	 diagnosis	
of	mucormycosis	were	receiving	a	polyene	prophylaxis,	and	12/61	
(20%)	of	cases	with	Aspergillosis	(proven	and	probable)	were	receiv-
ing an Aspergillus	active	antifungal	prophylaxis.
3.4.2 | Antifungal therapy
Table	3	 shows	 the	antifungal	 therapy	administered	 to	84/89	pa-
tients	 for	 at	 least	 of	 5	days.	 Forty-	two	 per	 cent	 of	 the	 patients	
(35/84)	received	only	one	line	of	therapy	while	58%	(49/84)	2	or	
more	 lines,	without	significant	differences	between	 IFI-	CNS	and	
IFI-	PS.	Combination	therapy,	with	2	or	more	antifungals,	was	ad-
ministered	in	38%	of	cases	and	was	employed	in	a	significant	higher	
number	of	cases	with	PS	involvement	(32%	vs	61%,	P	=	0.03).	The	
median	duration	of	antifungal	therapy	was	60	days	(range	5-	835).
In	detail,	in	the	49	cases	of	Aspergillosis	of	CNS,	the	antifungal	
agents	most	 frequently	 used	 as	 first-	line	 treatment	were	AMB	 (in	
28	cases)	and	VORI	 (in	24	cases),	alone	or	 in	combination.	The	12	
cases	of	Aspergillosis	of	PS	were	treated	in	the	first	line	mainly	with	
AMB	(9	cases)	and	with	VORI	(3	cases);	a	combination	therapy	was	
administered	only	 in	1	case.	Of	the	20	cases	of	Mucormycosis	 (15	
CNS	and	5	PS),	19/20	received	a	first-	line	antifungal	therapy	for	at	
least	5	days:	AMB	was	administered	to	9	patients,	AMB	+	POSA	to	
8	patients,	AMB	+	CASPO	to	1	patient	and	POSA	to	1	patient.	All	4	
cases	of	Cryptococcosis	received	FLUCO	and	AMB	(3/4	cases),	and	
the	2	cases	of	Fusariosis	received	AMB	plus	VORI.
Excisional	surgery	was	performed	 in	26%	of	the	cases	 (22/84),	
more	 often	 in	 patients	with	 IFI-	PS	 (33%)	 as	 compared	 to	 IFI-	CNS	
(10%)	(P	=	0.028).
The	 overall	 response	 rate	 (ORR)	 to	 treatment	 was	 57%	 (with	
CR	 34%	 and	 PR	 23%),	 without	 significant	 differences	 between	
F IGURE  1  (A)	Overall	Survival	from	
IFI	Diagnosis—All	Cases.	(B)	OS	from	IFI	
Diagnosis—according	to	site	(CNS	or	PS)
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the	2	cohorts	 (Table	3).	The	ORR	 in	 the	cases	of	Aspergillosis	and	
Mucormycosis	was	53%	and	52%,	respectively.
3.5 | Outcome
Median	survival	of	the	entire	patient	population	was	3.5	months	after	
the	diagnosis	of	IFI	(IFI-	CNS	3,3	mths	and	IFI-	PS	4,7	mths)	with	a	12-	
month	OS	probability	of	32%	(Figure	1A).	The	12-	month	OS	was	23%	in	
IFI-	CNS	and	34%	in	IFI-	PNS	(Log-	rank,	P	>	0.05)	(Figure	1B).	The	overall	
mortality	was	69%	(61/89)	without	a	significant	difference	between	the	
two	groups.	The	mortality	rate	for	IFI	as	the	primary	cause	(attributable	
mortality)	was	33%	(20/61	cases)	while	the	mortality	from	haematolog-
ical	disease	with	IFI	as	a	contributory	factor	was	44%	(27/61)	(Table	3).
Univariate	and	multivariate	analysis	of	the	variables	potentially	in-
fluencing	the	OS	are	shown	in	Table	4.	Analyses	have	been	restricted	
to	66	IFI-	CNS	that	received	antimycotic	treatment	 (Table	3).	 In	de-
tail,	 the	 following	 variables	 were	 checked	 and	 compared:	 isolated	
IFI-	CNS	vs	non-	isolated	forms,	proven	vs	probable	IFI,	Aspergillosis	
vs	other	aetiological	agents,	PMNs	lower	or	higher	than	500	at	the	
diagnosis	 of	 IFI,	 previous	Allo-	SCT,	 status	of	 haematologic	 disease	
(induction-	consolidation	vs.	refractory	disease	or	relapse),	response	
to	antifungal	therapy	(CR	or	PR	vs	not	response),	use	(yes	or	not)	of	
combination	antifungal	therapy	and	surgical	intervention	(yes	or	not).
In	univariate	analysis,	 the	following	factors	were	found	to	pro-
vide	a	favourable	effect	on	OS:	the	haematological	disease	at	onset	
or	 in	 consolidation	 (non-	advanced	 disease)	 (95%	 CI:	 1.007-	3.468;	
P	=	0.048)	and	the	response	(CR	or	PR)	to	antifungal	therapy	(95%	
CI:	5.081-	20.555;	P	<	0.0001).	The	same	variables	maintained	signif-
icance	in	multivariate	analysis	(95%	CI:	1,191-	5,507;	P	=	0.016;	95%	
CI:	6.631-	35.652;	P	<	0.0001)	(Table	4).
4  | DISCUSSION
IFIs	with	localisation	at	CNS	and	PS	are	a	rare	and	severe	infectious	
complication	in	the	course	of	haematological	diseases.	The	diagnosis	
of	such	infectious	complications	can	be	complex	because	the	symp-
toms	and	signs	are	not	specific,	indirect	microbiology	techniques	are	
not	validated	on	all	biological	fluids	(i.e,	CSF),	and	biopsy	is	often	dif-
ficult	in	patients	with	underlying	haematological	malignancies.1	In	the	
cases	of	CNS	or	PS-	IFI,	the	antifungal	treatment	is	frequently	associ-
ated	with	a	poor	efficacy	and	this	is	due	both	to	the	poor	permeability	
of	antifungal	drugs	in	anatomical	sites	(such	as	CNS)	and	to	the	inabil-
ity,	in	most	cases,	to	integrate	drug	therapy	with	surgery.1,9,12
Unfortunately,	 recent	epidemiological	studies	 involving	 large	co-
horts	of	haematological	patients	with	IFI-	CNS	or	IFI-	PS	are	lacking	and,	
TABLE  4 Univariate	and	multivariate	analyses	of	factors	that	influenced	overall	survival	in	66	cases	of	IFI-	CNS	who	received	treatment
SE P Exp 95%CI
Univariate	analysis
Status	of	HD	(Induction-	consolidation	vs	refractory	
or	relapse)
0.317 0.048 1.869 1.0072-	3.4681
Response	to	antifungal	therapy	(CR/PR	vs	NR) 0.3583 <0.0001 10.2201 5.0814-	20.5557
Proven	vs	probable	IFI 0.3049 0.338 0.7468 0.4121-	1.3534
Causative	agent	(Aspergillus	vs	Others) 0.3192 0.826 1.0725 0.5756-	1.9983
Isolated	IFI-	CNS	vs	non-	isolated	forms 0.3418 0.403 0.752 0.3862-	1.4643
Age	at	IFI-	CNS	diagnosis	(<	or	>	65	y) 0.3922 0.1564 1.7434 0.8114-	3.7457
PMN	(<	or	>	500/mmc) 0.3035 0.849 1.0591 0.5860-	1.9143
Allo-	SCT	(yes	or	not) 0.3156 0.195 0.6646 0.3591-	1.2298
Surgical	resection	(yes	or	not) 0.3618 0.26 1.503 0.7423-	3.0434
Combination	antifungal	therapy	(yes	or	not) 0.3251 0.614 1.1778 0.6249-	2.2200
Multivariate	analysis
Status	of	HD	(Induction-	consolidation	vs	refractory	
or	relapse)
0.3925 0.0165 2.5618 1.1916-	5.5076
Response	to	antifungal	therapy	(CR/PR	vs	NR) 0.4313 ≤0.0001 15.3755 6.6310-	35.6520
Proven	vs	probable	IFI 0.4848 0.7513 0.8575 0.3332-	2.2072
Causative	agent	(Aspergillus	vs	Others) 0.5498 0.4177 1.5613 0.5345-	4.5609
Isolated	IFI-	CNS	vs	non-	isolated	forms 0.3841 0.409 1.3732 0.6493-	2.9043
Age	at	IFI-	CNS	diagnosis	(<	or	>	65	y) 0.5183 0.7727 0.8609 0.3134-	2.3654
PMN	(<	or	>	500/mmc) 0.3463 0.0825 1.8246 0.9287-	3.5848
Allo-	SCT	(yes	or	not) 0.3777 0.485 1.3018 0.6232-	2.7191
Surgical	resection	(yes	or	not) 0.4996 0.3171 1.6485 0.6222-	4.3674
Combination	antifungal	therapy	(yes	or	not) 0.493 0.8426 1.1029 0.4217-	2.8844
HD,	haematologic	disease;	Allo-	SCT,	allogeneic	stem	cell	transplant;	PMN,	granulocytes.
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therefore,	there	are	no	established	diagnostic-	therapeutic	approaches	
to	 this	 serious	 infectious	 complication	 particularly	 in	 patients	 with	
haematological	malignancies	although,	more	recently,	attempts	have	
been	made	to	define	guidelines	based	on	experts’	opinion.12
This	study	shows	that,	even	 in	the	most	recent	years,	the	IFI	of	
CNS	and	PS	are	a	very	rare	infectious	complication	in	haematological	
patients.	In	fact,	in	the	34	centres	participating	in	this	study,	less	than	
1	case	per	centre	per	year	was	observed.	With	regard	to	the	under-
lying	haematological	disease,	most	of	the	cases	were	observed	in	pa-
tients	with	AML	and	ALL	or	in	recipients	of	an	allogeneic	SCT.1,17,18	In	
most	cases,	patients	had	an	active	disease	at	the	time	of	the	onset	of	
IFI	while	few	cases	occurred	with	a	haematological	disease	in	remis-
sion	or	during	the	consolidation	phase.	Although	74%	of	patients	were	
neutropenic,	 severe	neutropenia	 (PMN	<500/mmc)	has	been	docu-
mented	in	less	than	50%	of	cases	at	the	time	of	diagnosis	of	IFIs.	This	
confirms	that,	 in	addition	to	neutropenia,	other	factors,	such	as	the	
active	state	of	the	underlying	haematological	disease	and	the	degree	
of	patient’s	immunodepression,	play	an	important	predisposing	role.1
We	also	confirm	that	IFI-CNS	are	frequently	associated	with	con-
comitant	involvement	of	other	sites	(for	instance	in	the	lung).	In	fact,	
isolated	 IFI-	CNS	 forms	 accounted	 for	 only	 25%	of	 the	 cases	 in	 this	
study.	This	confirms	the	aetiopathogenic	hypothesis	that	the	IFI-	CNS	
could	originate	from	the	haematogenous	dissemination	of	an	infection	
arising	from	another	primary	site	(such	as	the	lung).1,11,19	In	this	study,	
a	pulmonary	IFI	has	preceded	a	CNS	or	PS	localisation	in	48%	of	cases.	
Therefore,	 in	 patients	 with	 pulmonary	 mycosis,	 the	 persistence	 of	
fever,	despite	a	pulmonary	improvement,	or	the	onset	of	a	headache	or	
other	neurological	signs,	such	as	diplopia,	should	never	be	underesti-
mated.	With	regard	to	the	diagnosis	of	IFIs,	our	data	show	that	indirect	
methods	of	diagnosis	are	now	commonly	used	 including	radiological	
examinations	 and	 biological	markers	 such	 as	GM,	which	 represents	
a	well	consolidated	diagnostic	method.1,9,12,20-24 β-	D-	Glucan	appears	
not	to	be	widely	used,	both	for	blood	and	CSF.	The	histological	diagno-
sis	remains	rarely	used,	even	in	the	recent	period	of	this	study	(histo-
logical	diagnosis	was	made	only	in	29%	of	cases).	In	addition,	it	should	
be	noted	that,	while	diagnostic	biopsy	of	PS	was	performed	in	69%	of	
cases,	brain	diagnostic	biopsy	was	performed	only	in	10%	of	IFI-	CNS	
and	mainly	in	patients	with	a	platelet	count	>100,000/mmc.
In	our	series	of	IFI-	CNS,	while	serum	GM	was	systematically	per-
formed,	GM	on	CSF	was	tested	in	a	limited	percentage	(42%)	of	cases,	
but	in	cases	where	this	test	was	performed,	it	was	positive	and,	there-
fore,	informative	in	67%	of	cases.	This	information	underlines	that	the	
determination	of	GM	in	CSF	can	be	useful	in	the	diagnosis	of	CNS-	
Aspergillosis,	and	therefore,	a	diagnostic	lumbar	puncture	should	be	
encouraged	in	cases	with	a	suspected	CNS	fungal	infection.1,20,25	On	
the	other	hand,	we	found	that	β-	D-	Glucan	has	only	been	occasion-
ally	determined	on	CSF,	although	this	is	a	very	recent	epidemiologic	
study.	This	indirect	diagnostic	test	on	the	CSF	should,	therefore,	be	
useful,	also	in	accordance	with	recent	literature	results.1,9,12,22,25
From	a	therapeutic	point	of	view,	the	study	confirms	that,	even	in	
the	most	recent	years,	surgical	treatment	has	been	used	in	a	minority	
of	cases,	both	in	the	forms	of	IFI-	PS	(surgery	in	33%	of	cases)	and	espe-
cially	in	the	IFI-	CNS	(surgery	only	in	10%	of	cases).	This	low	percentage	
of	surgery	is	similar	to	that	of	older	studies,	and	it	is	probably	related	
to	various	factors	such	as	the	presence	of	disseminated	infection,	the	
localisation	of	the	lesion	and	the	high	surgical	risk	related	to	severe	and	
prolonged	 thrombocytopenia	 and	 immunopression	 that	make	 these	
patients	at	high	risk	of	post-	operative	infections	and	bleeding.1,26
However,	compared	to	older	studies,	we	have	observed	an	 im-
provement	in	the	response	to	therapy	with	an	ORR	of	57%	(IFI-	CNS	
ORR	=	54%,	 IFI-	PS	 ORR	=	67%),	 and	 this	 is	 probably	 due	 to	 the	
availability	of	drugs,	such	as	VORI	and	AMB,	able	to	penetrate	well	
into	the	CNS	and	PS.	In	fact,	the	most	commonly	used	therapeutic	
agents	in	our	series	were	AMB	as	the	first-	line	treatment	(followed	
by	VORI)	and	VORI	as	second	line	(followed	by	AMB).	Additionally,	a	
non-	negligible	percentage	of	cases	(38%)	received	combination	anti-
fungal	therapy.
Unfortunately,	 the	 median	 OS	 of	 treated	 cases	 was	 short	
(3.5	months)	with	a	12-	month	OS	of	32%.	Sixty-	nine	per	cent	(61/89)	
of	 patients	 died,	 but	 it	 should	 be	 emphasised	 that	many	patients	
died	 from	 the	 underlying	 haematological	 disease	 as	 the	 primary	
cause	of	death.12,27-29	In	fact,	the	attributable	mortality	was	lower	
(33%)	respect	to	older	studies.	Another	interesting	observation	that	
comes	from	this	study	is	that	we	did	not	find	significant	differences	
in	terms	of	attributable	mortality	when	comparing	IFI-	PS	with	those	
of	CNS.	In	univariate	and	multivariate	analyses	(performed	for	the	
larger	cohort	of	patients	with	IFI-	CNS),	the	factors	that	were	found	
to	affect	OS	are	 the	 response	 (CR	or	PR)	 to	antifungal	 treatment	
and	the	status	of	haematologic	disease	(not	in	an	advanced	stage).
In	conclusion,	despite	 the	 limitations	of	a	 retrospective	obser-
vational	study,	this	is	one	of	the	largest	recent	epidemiological	se-
ries	of	IFI-	CNS	and	PS	in	haematological	patients.	This	study	shows	
that	these	infectious	complications	still	have	a	high	mortality	rate.	
However,	 compared	 to	older	epidemiological	data,	 there	 is	 a	 sub-
stantial	 improvement	 in	 the	response	rate	 to	 treatment	 (from	 less	
than	20%	to	more	than	50%)	and	in	patient	outcome	(overall	mor-
tality	from	100%	to	69%).3,30,31	There	is	likely	to	be	further	room	for	
improvement,	taking	into	account	the	current	availability	of	new	an-
tifungal	drugs	with	a	broad	spectrum	of	action	and	with	penetrabil-
ity	in	PS	and	CNS,	such	as	isavuconazole	and	the	available	possible	
option	of	combination	antifungal	therapy.9,32,33	Furthermore,	the	im-
provement	of	the	diagnostic	approach	with	the	execution,	in	cases	
of	 suspected	brain	mycosis,	 of	 a	diagnostic	 lumbar	puncture	with	
GM	and	β-	D-	Glucan	tests	in	CSF	samples	(or	new	PCR	assay)	could	
allow	a	better	and	faster	diagnostic	definition	and	consequently	a	
timely,	targeted	and,	therefore,	more	effective,	therapy.1,12,20,25,34
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